Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $15.2 million.

  • Ptc Therapeutics' Cash from Financing Activities rose 18633.91% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.1 million, marking a year-over-year decrease of 9352.13%. This contributed to the annual value of $255.9 million for FY2024, which is 6041.68% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Cash from Financing Activities stood at $15.2 million, which was up 18633.91% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Cash from Financing Activities ranged from a high of $620.5 million in Q4 2023 and a low of -$140.0 million during Q3 2022
  • Its 5-year average for Cash from Financing Activities is $58.9 million, with a median of $4.1 million in 2023.
  • The largest annual percentage gain for Ptc Therapeutics' Cash from Financing Activities in the last 5 years was 685723.47% (2022), contrasted with its biggest fall of 480413.31% (2022).
  • Ptc Therapeutics' Cash from Financing Activities (Quarter) stood at $4.4 million in 2021, then soared by 6857.23% to $302.9 million in 2022, then soared by 104.84% to $620.5 million in 2023, then crashed by 95.73% to $26.5 million in 2024, then plummeted by 42.51% to $15.2 million in 2025.
  • Its Cash from Financing Activities was $15.2 million in Q3 2025, compared to $4.0 million in Q2 2025 and $9.4 million in Q1 2025.